Eevia Health Plc, ("Eevia" or "The Company"), has received a large sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.
The sales value of this order is c.335,000 EUR and the product is Feno-Myrtillus 25 bilberry extract. The order is expected to create repeat sales of this product going forward.
"I am very pleased to see how our berry extracts are included in more and more nutraceutical products. It is great to see that our strategy of providing high quality, 100 % organic ingredients from the arctic region is paying off. I look forward to more business from the Australian market and I am happy about the great cooperation with our distributor Ingredients Plus." Stein Ulve, CEO
The Feno-Myrtillus® product range is extracted from arctic bilberries. The powder is deep blue, almost black due to the high concentration of the anthocyanins. These are likely to be the key bioactive compound responsible for several health benefits of bilberry extracts, as well as its high antioxidant potency.
This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on December 28, 2021.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc Kim Nurmi-Aro, CFO, Eevia Health Plc
Telephone: +358 400 22 5967 +358 504 44 0717
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild-harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product; Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. The factory operates near the raw material harvest areas. A uniquely short value chain enables an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.
Eevia Health Plc ("Eevia" or "The Company") is welcoming Tuomas Jylhä as interim Chief Financial Officer. Gabriella Beni has decided to leave the Company for personal reasons to focus on private matters. Eevia wishes her the very best in her future endeavors. Tuomas Jylhä will take over the position on July 26th.
Analyst Group Initiates equity research Coverage of Eevia Health Plc, ("Eevia" or "The Company").
Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus.
Eevia Health Plc, ("Eevia" or "The Company"), has received a 21 KEUR sales order from its Australian distributor Ingredients Plus for a new product made from Lingonberry, after a new customer has decided to launch a new product with the Lingonberry ingredient as a key component.
Eevia Health Plc, ("Eevia" or "The Company"), has entered into an agreement whereby Exelity AB, Sweden will provide a credit line for Eevia of up to SEK 8 million, giving the Company increased working capital flexibility to finance its continued growth.
The Annual General Meeting of Shareholders of Eevia Health Plc, corp. reg. no 2825194-4 (the "Company") was held on June 21, 2022 in Seinäjoki, Finland, whereby the shareholders primarily resolved the following matters:
Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from its Australian distributor Ingredients Plus. Ingredients Plus serves leading nutraceutical brands in Oceania and Asia with high-quality ingredients. The end customer is a major natural health company based out of Sydney, Australia selling its products across Asia and Oceania.
The shareholders of Eevia Health Abp, company registration number 2825194-4 in Finland, are hereby called for the Annual General Meeting (AGM) to be held on June 21st 2022.
Eevia Health Plc's (''Eevia'' or ''the Company'') Financial Statements for 2021 together with the Auditors' report have been published today.